Identification of human tumor antigens by serological analysis of recombinant cDNA expression libraries (SEREX) Journal Article


Author: Scanlan, M. J.
Article Title: Identification of human tumor antigens by serological analysis of recombinant cDNA expression libraries (SEREX)
Abstract: The structural definition of human tumor antigens recognized by the autologous host has been a long-standing challenge in tumor immunology. The growing list of human tumor antigens recognized by autologous antibodies or cytotoxic T lymphocytes provides convincing evidence for immune recognition of cancer by the host of origin, as well as attractive targets for vaccine-based approaches to cancer therapy. In this regard, an approach called SEREX (serological analysis of recombinant cDNA expression libraries) has broad applicability to the analysis of the humoral immune response to cancer antigens. This method involves immunoscreening cDNA libraries prepared from tumor specimens with sera from cancer patients in order to identify gene products recognized by IgG antibody. Clones identified by SEREX can be directly sequenced, providing immediate structural definition of the antigenic target, and their expression profiles can be readily determined, providing information regarding their tissue distribution. Application of this technique has led to the discovery of a number of provocative tumor antigens.
Keywords: neoplasm; neoplasms; gene library; tumor antigen; immunology; antigens, neoplasm; recombinant proteins; recombinant protein; antibodies, neoplasm; antiserum; complementary dna; dna, complementary; cancer antibody; immune sera
Journal Title: Current Protocols in Immunology
Volume: 65
ISSN: 1934-3671
Publisher: John Wiley & Sons  
Date Published: 2005-03-01
Start Page: 20.7.1
End Page: 20.7.19
Language: English
PUBMED: 18432945
PROVIDER: scopus
DOI: 10.1002/0471142735.im2007s65
DOI/URL:
Notes: --- - "Cited By (since 1996): 1" - "Export Date: 24 October 2012" - "Source: Scopus"
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Matthew J Scanlan
    49 Scanlan